U.S. Joint Pain Injections Market Size, Share & Industry Analysis, By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, and Others), By Joint Type (Knee, Hip, Hand & Wrist, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2024-2032

The U.S. joint pain injections market size was worth USD 2.16 billion in 2023 and is projected to grow at a CAGR of 11% during the forecast period. 

The prevalence of rheumatoid arthritis, osteoarthritis, and other musculoskeletal disorders among the U.S. adult population and children is rising. For instance, according to 2020 statistics published by CDC, around 32.5 million U.S. adults suffer from osteoarthritis. The increased awareness of the conditions and improved diagnosis rate in the country supports the market’s growth of joint pain injections and therapies.

Major industry players are actively focused on research and development activities for developing novel therapies in pain management.  According to the 2022 Sanofi annual report, there are around 14 new molecular entities in immunology and inflammation in the pipeline.  Also, the increased efforts of the key players to expand their geographical footprint supports the accessibility of the products in developing countries. The COVID-19 impact on the market was negative due to decreased patient visits to hospitals and clinics to treat joint disorders. The cancellation or postponement of appointments by the patients owing to the fear of contraction of COVID-19 infection hindered the U.S. joint pain injections market growth in 2020.

LATEST TRENDS

Increasing Number of Minimally Invasive Procedures for Musculoskeletal Disorders 

The administration of steroid injections is considered a minimally invasive procedure for joint pain. There are several advantages of minimally invasive surgical procedures for joint disorders, such as reduced pain, reduced bleeding, and rapid recovery, among others which lead to an increased preference for minimally invasive surgeries among patients. The adoption of joint pain injections among healthcare providers is due to their clinical advantages, such as drug adsorption and a longer relief period for patients.

Additionally, there are several ongoing clinical trials for various stem cell therapies to treat joint pain, which is currently a trend for joint pain management.

DRIVING FACTORS

Rising Incidence of Sports Injuries and Awareness Regarding Joint Disorders to Foster the Demand in the Market

There is a growing incidence of sports injuries resulting in frequent muscle tears, joint pain, and fractures, among others. Moreover, the prevalence of musculoskeletal conditions leading to severe joint pain and other issues is also on the rise among the adult population in the U.S. According to a study conducted by the Burden of Musculoskeletal Conditions in the U.S., more than half of the American population over the age of 18 (54.0%) are affected by musculoskeletal (bone and joint) conditions.

The number of sports injuries increased after the COVID-19 pandemic due to lockdown restrictions and reopening of sports clubs, schools, universities, and others.

According to the 2021 article published by the National Safety Council, sports and recreational injuries increased by around 20% in 2021 compared to the previous year. 

Request a Free sample to learn more about this report.

RESTRAINING FACTORS

Complications Associated with the Administration of Joint Pain Injections  

The use of joint pain injections for the long term may pose short or long-term complications among the patients, such as intense pain and swelling at the site of injection, stress fractures, and collapse of joints, among others.

According to a report published by the Radiological Society of North America, a recent retrospective observational study by Simeone et. al focused on intra-articular corticosteroid injection in the hip and subsequent joint events in 70 patients. They reported that 17.0% of patients developed articular surface collapse and even more adverse joint pain events.

Also, the high cost of hyaluronic acid injections for osteoarthritis and other joint disorders is expected to hamper the patient’s demand for these injections.

SEGMENTATION

By Product Analysis

Based on product, the market is segmented into corticosteroid injections, hyaluronic acid injections, platelet rich plasma injections, and others.  

The hyaluronic acid injections segment dominated the U.S. joint pain injections market share in 2022. The dominance is attributed to the increasing adoption of visco-supplement injections, owing to favorable reimbursement policies in the U.S. for the treatment of osteoarthritis.

According to CMS, Medicare covers hyaluronic injections for pain management approved by the U.S. FDA and provides coverage to patients for one injection every 6 months.

By Joint Type Analysis

Based on joint type, the market is segmented into knee, hip, hand & wrist, and others.

The knee segment held the largest U.S. market share in 2022 and is expected to grow at a moderate CAGR during the forecast period. The prevalence and risk of knee osteoarthritis among the geriatric population is rising in the country. The growing geriatric population with a higher risk of the condition is expected to foster the segment's growth during the forecast period.

As per a 2022 article published by National Center for Biotechnology & Information, it was reported that the incidence of symptomatic knee osteoarthritis is approximately 240 cases per 100,000 people per year.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The retail pharmacies segment dominated the market in 2022 and is expected to grow at a considerable CAGR during the forecast period. The segment’s growth is attributed to the rising number of retail pharmacies in the country and the growing demand for injections.

KEY INDUSTRY PLAYERS

The U.S. joint pain injections market is a fragmented market with numerous players in the country.

Some key players of this injections are Bioventus, Anika Therapeutics, Inc., Zimmer Biomet, and Teva Pharmaceutical Industries Ltd. The rising R&D focus of these companies is to develop and introduce novel products for treating various musculoskeletal disorders in the country.

For instance, in November 2022, Anika Therapeutics, Inc. announced that Cingal met its primary endpoint in a Phase III Study, demonstrating superiority over triamcinolone hexacetonide (TH) steroid alone at 26 weeks post-treatment.

Other prominent players of joint pain injections include Ferring B.V., SEIKAGAKU CORPORATION, and Pacira BioSciences, Inc., among others. The robust efforts of these players to penetrate the U.S. market with their product portfolio through mergers and acquisitions is one of the important factors supporting the growing market share of these players.

LIST OF KEY COMPANIES PROFILED:

• Sanofi (France)


• SEIKAGAKU CORPORATION (Japan)


• Bioventus (U.S.)


• Anika Therapeutics, Inc. (U.S.)


• Pacira BioSciences, Inc. (U.S.)


• Dr. Reddy’s Laboratories Ltd. (India)


• Zimmer Biomet (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Ferring B.V. (Switzerland)

KEY INDUSTRY DEVELOPMENTS: 

• April 2022 – Dr. Reddy’s Laboratories Ltd. launched Methylprednisolone Sodium Succinate for Injection, USP. It is a generic equivalent of SOLU-MEDROL in the U.S. for the treatment of blood disorders, arthritis, and other allergic conditions.


• March 2022 - Anika Therapeutics, Inc. announced that it will showcase its comprehensive joint preservation and restoration product portfolio at the 2022 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on March 23 - 25 in Chicago, U.S.


• May 2020 - Teva Pharmaceuticals USA, Inc., and Celltrion Healthcare Co., Ltd., announced that TRUXIMA (rituximab-abbs) injection is now available in the U.S. for the treatment of Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active rheumatoid arthritis.

REPORT COVERAGE

The market research report provides a detailed analysis of the market. It focuses on key aspects, including technological advancements, the prevalence of rheumatoid arthritis, musculoskeletal disorders in the U.S., and pricing analysis. Additionally, it includes the latest trends in the market, new product launches, key industry developments, including mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. In addition to the aforementioned factors, it includes several factors that contributed to the growth of the market in recent years.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation